Free Trial
NASDAQ:TRAW

Traws Pharma Q1 2025 Earnings Report

Traws Pharma logo
$1.63 -0.06 (-3.55%)
Closing price 04:00 PM Eastern
Extended Trading
$1.67 +0.04 (+2.45%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Traws Pharma EPS Results

Actual EPS
$2.09
Consensus EPS
-$8.04
Beat/Miss
Beat by +$10.13
One Year Ago EPS
N/A

Traws Pharma Revenue Results

Actual Revenue
$0.06 million
Expected Revenue
$0.06 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Traws Pharma Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Traws Pharma's Q2 2025 earnings is scheduled for Thursday, August 21, 2025, with a conference call scheduled on Thursday, August 14, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Traws Pharma Earnings Headlines

TRAW - Traws Pharma Inc Sustainability - Morningstar
A grave, grave error.
Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one analyst who predicted the collapse of Fannie Mae and GM says the AI giant is now headed for a brutal crash… and it could hit as soon as this year.
See More Traws Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Traws Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Traws Pharma and other key companies, straight to your email.

About Traws Pharma

Traws Pharma (NASDAQ:TRAW), a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

View Traws Pharma Profile

More Earnings Resources from MarketBeat